- Report
- February 2026
- 250 Pages
Global
From €4089EUR$4,490USD£3,526GBP
- Report
- February 2026
- 250 Pages
Global
From €4089EUR$4,490USD£3,526GBP
- Report
- February 2026
- 250 Pages
Global
From €4089EUR$4,490USD£3,526GBP
- Report
- June 2026
- 570 Pages
Global
From €5327EUR$5,850USD£4,594GBP
- Report
- June 2026
- 284 Pages
Global
From €5327EUR$5,850USD£4,594GBP
- Report
- June 2026
- 372 Pages
Global
From €5327EUR$5,850USD£4,594GBP
- Report
- June 2026
- 273 Pages
Global
From €5327EUR$5,850USD£4,594GBP
- Report
- June 2026
- 375 Pages
Global
From €5327EUR$5,850USD£4,594GBP
- Report
- June 2026
- 273 Pages
Global
From €5327EUR$5,850USD£4,594GBP
- Report
- June 2026
- 179 Pages
Global
From €5327EUR$5,850USD£4,594GBP
- Report
- November 2025
- 200 Pages
Global
From €7239EUR$7,950USD£6,243GBP
- Report
- November 2025
- 200 Pages
Global
From €7239EUR$7,950USD£6,243GBP
- Report
- April 2026
- 195 Pages
Global
From €4325EUR$4,750USD£3,730GBP
- Report
- November 2025
- 200 Pages
Global
From €7239EUR$7,950USD£6,243GBP
- Report
- October 2025
- 198 Pages
Global
From €4098EUR$4,500USD£3,534GBP
- Report
- July 2025
- 350 Pages
Global
From €4507EUR$4,949USD£3,886GBP
- Report
- September 2025
- 150 Pages
Global
From €4416EUR$4,850USD£3,809GBP
- Report
- April 2026
- 137 Pages
Global
From €3500EUR$4,117USD£3,124GBP
- Report
- September 2025
- 150 Pages
Global
From €4052EUR$4,450USD£3,495GBP
- Report
- April 2026
- 128 Pages
Global
From €3500EUR$4,117USD£3,124GBP

Lymphoma is a type of hematological malignancy that originates in the lymphatic system. It is characterized by the uncontrolled growth of lymphocytes, a type of white blood cell. Lymphomas can be either Hodgkin's or non-Hodgkin's, and can be either indolent or aggressive. Treatment options for lymphoma include chemotherapy, radiation therapy, stem cell transplantation, and targeted therapies.
The lymphoma market is a subset of the larger hematology market, which includes treatments for a variety of blood-related diseases. The lymphoma market is driven by the increasing prevalence of the disease, as well as the development of new treatments.
Companies in the lymphoma market include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Celgene, Gilead Sciences, Novartis, and Pfizer. Show Less Read more